<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348972</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901/1021</org_study_id>
    <secondary_id>HOE901</secondary_id>
    <nct_id>NCT00348972</nct_id>
  </id_info>
  <brief_title>Lantus in Prediabetes</brief_title>
  <official_title>Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes&#xD;
      (IFG or IGT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: 8-point blood glucose measurements.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety / tolerability: hypoglycemia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood glucose in response to exercise.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting supine levels of counterregulatory hormones</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus® (insulin glargine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperglycemia (either IGT , IFG, or untreated type 2 diabetes)&#xD;
&#xD;
          -  HbA1c &lt; 7.0%&#xD;
&#xD;
          -  BMI &lt; 40kg/m2&#xD;
&#xD;
          -  Able to perform moderate stationary bicycle exercise&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic pharmacologic treatment for hyperglycemia, past or present&#xD;
&#xD;
          -  CAD&#xD;
&#xD;
          -  serum creatinine &gt; 2.0mg/dL&#xD;
&#xD;
          -  BP &gt; 180/105&#xD;
&#xD;
          -  History of hypoglycemia unawareness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter JOHNSTON, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>July 4, 2006</study_first_submitted>
  <study_first_submitted_qc>July 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>July 4, 2006</last_update_submitted>
  <last_update_submitted_qc>July 4, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2006</last_update_posted>
  <keyword>Glargine</keyword>
  <keyword>prediabetes</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>impaired fasting glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

